Literature DB >> 3933653

Is there a place for placebo controlled trials of antiepileptic drugs?

S D Shorvon, M L Espir, T J Steiner, C I Dellaportas, F C Rose.   

Abstract

In many patients who develop epilepsy the disease is short lived and the overall number of seizures small. The role of anticonvulsant drugs in such patients is uncertain. If treatment is merely suppressive and the disease self limiting then treatment may not be necessary in some patients. If, on the other hand, early treatment prevents the subsequent evolution to chronic epilepsy then it is imperative. To resolve this issue it is essential to undertake placebo controlled trials, in which a group of patients with newly diagnosed epilepsy is given active treatment and compared with a similar group given placebo alone.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3933653      PMCID: PMC1417400          DOI: 10.1136/bmj.291.6505.1328

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN: 0267-0623


  5 in total

1.  Remission of seizures and relapse in patients with epilepsy.

Authors:  J F Annegers; W A Hauser; L R Elveback
Journal:  Epilepsia       Date:  1979-12       Impact factor: 5.864

2.  Epileptic seizures in a population of 6000. II: Treatment and prognosis.

Authors:  D M Goodridge; S D Shorvon
Journal:  Br Med J (Clin Res Ed)       Date:  1983-09-03

3.  Epileptic seizures in a population of 6000. I: Demography, diagnosis and classification, and role of the hospital services.

Authors:  D M Goodridge; S D Shorvon
Journal:  Br Med J (Clin Res Ed)       Date:  1983-09-03

4.  The temporal aspects of prognosis in epilepsy.

Authors:  S D Shorvon
Journal:  J Neurol Neurosurg Psychiatry       Date:  1984-11       Impact factor: 10.154

5.  Early prognosis of epilepsy.

Authors:  S D Shorvon; E H Reynolds
Journal:  Br Med J (Clin Res Ed)       Date:  1982-12-11
  5 in total
  3 in total

1.  The course of untreated epilepsy.

Authors:  S Shorvon
Journal:  BMJ       Date:  1988-11-26

Review 2.  Vigabatrin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy and disorders of motor control.

Authors:  S M Grant; R C Heel
Journal:  Drugs       Date:  1991-06       Impact factor: 9.546

Review 3.  Newer antiepileptic drugs. Towards an improved risk-benefit ratio.

Authors:  P N Patsalos; J W Sander
Journal:  Drug Saf       Date:  1994-07       Impact factor: 5.606

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.